<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149721">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957488</url>
  </required_header>
  <id_info>
    <org_study_id>CP242</org_study_id>
    <nct_id>NCT01957488</nct_id>
  </id_info>
  <brief_title>Investigating the Safety and Performance of Two New 1-piece Ostomy Products Compared With SenSura 1-piece</brief_title>
  <official_title>Investigating the Safety and Performance of Two New 1-piece Ostomy Products in 180 Subjects With Ileostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current investigation is to investigate the performance of two  new 1-piece
      ostomy products
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present investigation aims at testing the performance and safety of the two new 1-piece
      ostomy products
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Leakage</measure>
    <time_frame>14 +/- 1 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Leakage is measured</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Ileostomy - Stoma</condition>
  <arm_group>
    <arm_group_label>Treatment sequence 1; First Coloplast Test product 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
Subjects first allocated to test Coloplast Test product 1 secondly test either:
Coloplast Test product 1 and thereafter Coloplast SenSura
Coloplast Sensura and thereafter Coloplast Test product 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment seqence 2; First Coloplast Test product 2.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
Subjects first allocated to test Coloplast Test product 2 secondly test either:
Coloplast Test product 1 and thereafter Coloplast SenSura
Coloplast Sensura and thereafter Coloplast Test product 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 3, First Coloplast SenSura</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
Subjects first allocated to test Coloplast SenSura secondly test either:
Coloplast Test product 2 and thereafter Coloplast Test product 1
Coloplast Test product 1 and thereafter Coloplast Test product 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coloplast Test Product 1</intervention_name>
    <description>Coloplast Test product 1 is a newly developed 1-piece ostomy appliance</description>
    <arm_group_label>Treatment sequence 1; First Coloplast Test product 1</arm_group_label>
    <arm_group_label>Treatment seqence 2; First Coloplast Test product 2.</arm_group_label>
    <arm_group_label>Treatment sequence 3, First Coloplast SenSura</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coloplast Test Product 2</intervention_name>
    <description>Coloplast Test product 2 is a newly developed 1-piece ostomy appliance</description>
    <arm_group_label>Treatment sequence 1; First Coloplast Test product 1</arm_group_label>
    <arm_group_label>Treatment seqence 2; First Coloplast Test product 2.</arm_group_label>
    <arm_group_label>Treatment sequence 3, First Coloplast SenSura</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coloplast SenSura</intervention_name>
    <description>SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.</description>
    <arm_group_label>Treatment sequence 1; First Coloplast Test product 1</arm_group_label>
    <arm_group_label>Treatment seqence 2; First Coloplast Test product 2.</arm_group_label>
    <arm_group_label>Treatment sequence 3, First Coloplast SenSura</arm_group_label>
    <other_name>SenSura 1-piece</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have given written informed consent and signed letter of authority (mandatory in DK)

          2. Be at least 18 years of age and have full legal capacity.

          3. Be able to handle the products themselves

          4. Have an ileostomy with a diameter between 10 and 40 mm.

          5. Have had their ostomy for at least three months.

          6. Have within the last month used a 1-piece flat product with open bag

          7. Currently using midi or maxi bags

          8. Willing to use minimum 1 product every second day, i.e. maximum 2 days wear time.

          9. Be suitable for participation in the investigation

         10. Must be able to use custom cut product

         11. Negative result of a pregnancy test for women of childbearing age (only DK)

        Exclusion Criteria:

          1. Currently receiving or have within the past 2 months received radio- and/or
             chemotherapy.

          2. Currently receiving or have within the past month received systemic steroid or local
             treatment in the peristomal area

          3. Are pregnant or breastfeeding

          4. Participating in other interventional clinical investigations or have previously
             participated in this investigation

          5. Has participated in the previous explorative Coloplast studies CP236 and CP237

          6. Are currently or during the study using ostomy belt

          7. Has a stoma below skin surface

          8. Currently suffering from peristomal skin problems (i.e.bleeding and/or broken skin)

          9. Has known hypersensitivity towards any of the test products
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birte P Jakobsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coloplast A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holtedam 3</name>
      <address>
        <city>Humleb√¶k</city>
        <zip>3050</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS Nederlands</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykepleierklinikken</name>
      <address>
        <city>Larvik</city>
        <zip>3269</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Limited</name>
      <address>
        <city>Lancashire</city>
        <zip>PR71NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 1, 2013</lastchanged_date>
  <firstreceived_date>August 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
